An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand.
about
Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: a novel mechanism for methylphenidate actionSigma receptors: potential targets for a new class of antidepressant drugKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyCurrent investigational drugs for major depressionPotentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptorsPotentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways.Cyclic adenosine monophosphate response element-binding protein phosphorylation and neuroprotection by 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP).Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction.Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis.Sigma receptor 1 modulates endoplasmic reticulum stress in retinal neurons.Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.Activation of σ-receptors induces binge-like drinking in Sardinian alcohol-preferring ratsInvolvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors.Cholesterol at the endoplasmic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases.The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements.Antagonism of sigma-1 receptors blocks compulsive-like eating.Synthesis and σ1 Receptor Binding of Halogenated N,N'-Diphenethylethylenediamines.Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.Sigma receptors [σRs]: biology in normal and diseased statesSequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress.Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway.sigma-1 receptors in major depression and anxiety.Caprospinol: discovery of a steroid drug candidate to treat Alzheimer's disease based on 22R-hydroxycholesterol structure and properties.An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments.Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder.Effects of BD1047, a σ1 receptor antagonist, on the expression of mTOR, Camk2γ and GSK-3β in fluvoxamine-treated N2a cells.Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.Radiosynthesis and in vivo evaluation of a novel σ1 selective PET ligand.Synthesis and in vitro evaluation of tetrahydroisoquinolines with pendent aromatics as sigma-2 (σ2) selective ligands.Involvement of GABAA receptors in 5-HT1A and σ1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency.The sigma agonist 1,3-di-o-tolyl-guanidine reduces the morphological and behavioral changes induced by neonatal ventral hippocampus lesion in rats.Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice.Inhibitory effects of sigma-1 ligands on handling-induced tachycardia in conscious tethered rats.Fluorinated PET Tracers for Molecular Imaging of σ1 Receptors in the Central Nervous System.The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases.Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.
P2860
Q21090824-C59EA225-F1C7-463A-A6CA-73BE63981C9AQ24567770-735BF484-BDDB-4143-A446-85B2D3F87636Q27024227-5735A42A-AAD8-438C-A522-069EC8925B67Q28244223-12A1B906-429B-41A4-8DAE-BF488E2F16D4Q28729237-F57C0AEF-AE18-451F-BC8F-4A3D745D3EEBQ33348563-70001B54-BE8C-4DF7-B8D6-C576A9893007Q33687849-C4DC4973-4C33-4C19-A928-0B23D0A7513DQ33754855-A084CC35-88DC-4E58-A293-043EE1981BABQ34462194-A03E66BB-339D-4A25-A2E7-3BEF5FAA2C87Q34646807-A4BD2A8E-EC71-4D30-9ED4-876BC772E6FDQ34795242-ACEFEAD8-CDFC-4F13-B44B-115515A17C2BQ34813687-089F51C2-09C2-4202-B7E6-0868FD2E7916Q35108500-66B14225-9CBF-4C0A-98C1-2A792E60CCC6Q35148443-C6A02FC4-5E58-4757-A999-5E904B8C143FQ35163209-AED9C9A0-C94E-4E10-82F5-4D1C4F525C6FQ35856904-19659F01-2881-4F06-97AA-F3DB36350392Q36323590-FF794BBF-1273-4549-8C30-49105D355BE1Q36737209-9D521AB2-D95F-42C3-B32B-D5A7AD88B38FQ36755305-0F1F8F1B-E377-4C64-AB30-EA1DA75F3FFCQ37000551-23667390-83C1-4F90-AF68-77516DB4AB7AQ37252082-429A01DB-B23C-4516-9850-D3F4F953DE93Q37471826-2E9913C1-66A8-4FDE-9DFD-130B3C1AFE7FQ37546082-C5AA0307-7C31-457E-B0D8-ED0F3D25534EQ37882023-43EEAD4A-3F9B-4425-B2AB-E9982D87B552Q38034731-3EA9EC49-EFA4-48B3-852D-5991C5304C5CQ38766222-F49682A7-852A-4BF1-B707-E96EAB91127BQ41851136-774FA540-FE34-47CA-8073-2EB5C16F8376Q41891428-293A1B0C-D0EF-41C6-BD83-0EBC091B6DF3Q42928981-B47A0581-414A-4DA8-B539-8886D1ADCDC8Q43097520-26F45596-2CD8-46C9-895A-75035DD9D70CQ45110819-E0153288-8DF3-4107-909F-C52F733405DCQ47416679-75651BBD-9D9D-4112-A545-84E22DF983D3Q47676693-AAA9F642-5BDD-40E3-93AF-B9407705F451Q47915510-B7DC82AC-35CE-4861-A63C-7D86B04ABF45Q48171791-0F27BDF4-7136-4774-B8DC-4DCCD2F80F89Q48258075-05149ED4-6292-4318-A4B2-84EAE9FC439AQ50973291-CA7F0F06-8B3E-4FAC-9222-5C48DF19643DQ51094803-9FC992A9-55DC-414D-97E2-B5962B54BEA5Q55340475-5E13216F-0206-4CF6-8DBC-F626B0F7052D
P2860
An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
An update on the development o ...... n the sigma 1 receptor ligand.
@ast
An update on the development o ...... n the sigma 1 receptor ligand.
@en
An update on the development o ...... n the sigma 1 receptor ligand.
@nl
type
label
An update on the development o ...... n the sigma 1 receptor ligand.
@ast
An update on the development o ...... n the sigma 1 receptor ligand.
@en
An update on the development o ...... n the sigma 1 receptor ligand.
@nl
prefLabel
An update on the development o ...... n the sigma 1 receptor ligand.
@ast
An update on the development o ...... n the sigma 1 receptor ligand.
@en
An update on the development o ...... n the sigma 1 receptor ligand.
@nl
P2860
P356
P1476
An update on the development o ...... n the sigma 1 receptor ligand.
@en
P2093
Teruo Hayashi
Tsung-Ping Su
P2860
P356
10.1517/14728222.12.1.45
P407
P577
2008-01-01T00:00:00Z